YSP Southeast Asia Holding Bhd banner
Y

YSP Southeast Asia Holding Bhd
KLSE:YSPSAH

Watchlist Manager
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
Watchlist
Price: 2.06 MYR
Market Cap: 292.2m MYR

EV/OCF

3.3
Current
32%
Cheaper
vs 3-y average of 4.9

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
3.3
=
Enterprise Value
MYR181.6m
/
Operating Cash Flow
54.5m

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
3.3
=
Enterprise Value
MYR181.6m
/
Operating Cash Flow
54.5m

Valuation Scenarios

YSP Southeast Asia Holding Bhd is trading below its 3-year average

If EV/OCF returns to its 3-Year Average (4.9), the stock would be worth MYR3.04 (48% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+261%
Average Upside
146%
Scenario EV/OCF Value Implied Price Upside/Downside
Current Multiple 3.3 MYR2.06
0%
3-Year Average 4.9 MYR3.04
+48%
5-Year Average 4.7 MYR2.91
+41%
Industry Average 11 MYR6.86
+233%
Country Average 11.9 MYR7.43
+261%

Forward EV/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward EV/OCF

Peer Comparison

All Multiples
EV/OCF
P/E
All Countries
Close
Market Cap EV/OCF P/E
MY
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
292.2m MYR 3.3 11.7
US
Eli Lilly and Co
NYSE:LLY
870.6B USD 53.7 42.2
US
Johnson & Johnson
NYSE:JNJ
544.4B USD 23.2 25.9
CH
Roche Holding AG
SIX:ROG
248.4B CHF 14.7 19.3
UK
AstraZeneca PLC
LSE:AZN
225.4B GBP 21.9 29.2
CH
Novartis AG
SIX:NOVN
222.8B CHF 15.5 20
US
Merck & Co Inc
NYSE:MRK
279.4B USD 18.9 15.3
IE
Endo International PLC
LSE:0Y5F
244.4B USD 936 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 10.1 10.8
US
Pfizer Inc
NYSE:PFE
152.4B USD 17.1 19.6
US
Bristol-Myers Squibb Co
NYSE:BMY
118.4B USD 10.7 16.8
P/E Multiple
Earnings Growth PEG
MY
Y
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
Average P/E: 21.1
11.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.2
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
25.9
8%
3.2
CH
Roche Holding AG
SIX:ROG
19.3
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
29.2
25%
1.2
CH
Novartis AG
SIX:NOVN
20
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.3
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.6
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1

Market Distribution

Lower than 90% of companies in Malaysia
Percentile
10th
Based on 364 companies
10th percentile
3.3
Low
0.3 — 7.4
Typical Range
7.4 — 19.2
High
19.2 —
Distribution Statistics
Malaysia
Min 0.3
30th Percentile 7.4
Median 11.9
70th Percentile 19.2
Max 44 111.4

YSP Southeast Asia Holding Bhd
Glance View

Market Cap
292.2m MYR
Industry
Pharmaceuticals

Y.S.P.Southeast Asia Holding Bhd. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2004-01-12. Southeast Asia Holding Bhd. is a Malaysia-based investment holding company that is primarily engaged in the provision of management services. The Company’s segments include Manufacturing, Trading and Investment holding. The Manufacturing segment is engaged in manufacturing of pharmaceutical products. The Trading segment is involved in import, export and trading of various kinds of pharmaceutical, traditional herbal and veterinary products. The Investment holding segment is engaged in investment holding. Its subsidiaries include Y.S.P. (Cambodia) Pte. Ltd., which is engaged in providing management services, such as product registration trademark registration and national marketing and trading in all kinds of pharmaceutical products, and Alpha Active Industries Sdn. Bhd., which is engaged in the manufacture of biotechnology products and health products.

YSPSAH Intrinsic Value
3.01 MYR
Undervaluation 32%
Intrinsic Value
Price MYR2.06
Y
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett